A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton TyrosineKinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
Study of BGB-16673 in Patients with Leukemia or Lymphoma
Sponsor: NA
Enrolling: Male and Female Patients
IRB Number: AAAU5330
U.S. Govt. ID: NCT05006716
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to look at the safety and tolerability of the study drug, BGB-16673. Another purpose is to determine the range of BGB-16673 doses that can safely be used. BGB-16673 is an experimental drug. This means that it has not been approved for treatment by the US, the Food and Drug Administration (FDA). This research study is the first time that BGB-16673 will be given to humans and therefore the effects of BGB-16673 on humans are not yet known.
Investigator
Nicole Lamanna, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with leukemia or lymphoma? Yes No
Are you able to swallow capsules? Yes No
Do you have a life expectancy of more than 6 months? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE